Nevertheless, a phase-I trial has been initiated to test the PARP14/ARTD8 inhibitor, RBN-3143, as a potential therapy for atopic dermatitis (Clinical Trial No.: NCT05215808), focusing on inflammation control. The gene discussed is PARP14; the disease is atopic eczema.